Xtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200 Day Moving Average - Should You Sell?

Key Points

• Xtant Medical's stock recently crossed above its 200-day moving average, reaching a high of $0.64 before closing at $0.62.
• Renaissance Technologies LLC increased its stake in Xtant Medical by 15.0%, now owning approximately 0.57% of the company valued at $354,000.
• The company's market cap is currently $86.38 million, with a P/E ratio of -6.89 and a quick ratio of 1.03.

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.54 and traded as high as $0.64. Xtant Medical shares last traded at $0.62, with a volume of 23,194 shares traded.

Xtant Medical Price Performance

The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.03 and a current ratio of 2.34. The stock has a market capitalization of $87.77 million, a price-to-earnings ratio of -7.00 and a beta of -0.14. The firm's fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.54.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC grew its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 798,033 shares of the medical device company's stock after acquiring an additional 103,825 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Xtant Medical worth $354,000 as of its most recent SEC filing. 69.33% of the stock is currently owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.